Geode Capital Management
CERO

Geode Capital Management’s CERo Therapeutics CERO Stock Holding History

Geode Capital Management’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-846
Closed -$12.3K – 4530
2025
Q1 		$12.3K Buy
+846
New +$33.4K ﹤0.01% 4419
2024
Q4 		– Sell
-79
Closed -$14.7K – 4520
2024
Q3 		$14.7K Buy
79
+55
+229% +$16.8K ﹤0.01% 4432
2024
Q2 		$14.4K Buy
24
+19
+380% +$44.1K ﹤0.01% 4506
2024
Q1 		$32.5K Hold
5
– – ﹤0.01% 4402
2023
Q4 		$117K Hold
5
– – ﹤0.01% 4137
2023
Q3 		$115K Hold
5
– – ﹤0.01% 4200
2023
Q2 		$114K Hold
5
– – ﹤0.01% 4285
2023
Q1 		$113K Hold
5
– – ﹤0.01% 4299
2022
Q4 		$109K Hold
5
– – ﹤0.01% 4367
2022
Q3 		$106K Buy
+5
New +$101K ﹤0.01% 4543

Other funds holding CERO

PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management's CERO Position: Q2 2025 in Review

Geode Capital Management sold out of CERo Therapeutics (CERO) in Q2 2025, closing a stake of 846 shares — an estimated $12.3K sold.

Geode Capital Management first reported a position in CERO in Q3 2022 and held it in 10 quarters. The position peaked at $117K in Q4 2023. 8 funds tracked by Wall St. Rank hold CERO as of Q2 2025.

  • Geode Capital Management reported no remaining CERo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Geode Capital Management sold 846 CERo Therapeutics shares in Q2 2025, an estimated $12.3K.
  • Geode Capital Management first reported a position in CERo Therapeutics in Q3 2022 and held it in 10 quarters.
  • Geode Capital Management's CERo Therapeutics position peaked at $117K in Q4 2023.
  • 8 funds tracked by Wall St. Rank held CERo Therapeutics as of Q2 2025.

Based on Geode Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.